Brief: Biofrontera Q4 Revenue USD 17.1 Million
19/03/2026 13:25
Mar 19 (Reuters) - Biofrontera Q4 net income USD 5.6 million. Q4 adjusted EBITDA USD 4.9 million Q4 operating expenses USD 12.5 million
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales